Testing a new diagnostic for celiac disease during endoscopy
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a new medicine called HB-2121 used as a diagnostic tool during an upper endoscopy to help improve detection of celiac disease. It's designed for people who are already scheduled for this procedure and may help doctors see the gut damage caused by celiac more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are scheduled for an upper endoscopy (EGD) because your doctor suspects celiac disease.
- You are generally healthy, with no major liver, kidney, or heart problems.
- You have not had cancer or used immune-suppressing medications.
- You agree to use highly effective birth control if you or your partner could get pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at better ways to diagnose celiac disease, a condition where eating gluten damages your small intestine. If you've recently had an endoscopy and a celiac blood test, your information could help improve how doctors diagnose this condition.
This study tests an experimental medication for adults with celiac disease to see if it can protect against gluten exposure. You will need to follow a gluten-free diet and undergo a short, planned gluten challenge.
This study helps people newly diagnosed with celiac disease learn to use a gluten-detection device and get education to better manage their diet and health.
This trial tests a new medicine, ZED1227, for people with celiac disease who still have symptoms despite eating gluten-free. The goal is to see if it helps reduce those symptoms.
This study uses ultrasound and blood tests to check how active celiac disease is, which may help doctors monitor the condition without needing invasive procedures.
This trial tests a new drug called DONQ52 in people with active celiac disease who still have symptoms despite following a gluten-free diet. The goal is to see if DONQ52 can help reduce damage to the small intestine and improve gluten-related symptoms.
Hear when a new Celiac Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.